Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology’s Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p

Genzyme (NASDAQ:GENZ)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Genzyme Charts.
Genzyme (NASDAQ:GENZ)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Genzyme Charts.